Verrica Pharmaceuticals/VRCA

$6.88

1.33%
-
1D1W1MYTD1YMAX

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Ticker

VRCA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Ted White

Employees

100

Headquarters

West chester, United States

VRCA Metrics

BasicAdvanced
$296.08M
Market cap
-
P/E ratio
-$1.46
EPS
1.80
Beta
-
Dividend rate
$296.08M
1.79914
$7.76
$2.86
137.14K
4.554
4.494
222.132
224.035
-51.74%
-106.07%
-224.08%
-126.6%
57.783
14.98
14.982
-43.27%
-78.42%

What the Analysts think about VRCA

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
88.95% upside
High $18.00
Low $8.00
$6.88
Current price
$13.00
Average price target

VRCA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,294.73% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.9M
-34.48%
Net income
$-24.6M
-0.81%
Profit margin
-1,294.73%
51.4%

VRCA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.38%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.15
-$0.24
-$0.54
-$0.53
-
Expected
-$0.19
-$0.21
-$0.36
-$0.53
-$0.40
Surprise
-21.05%
14.18%
49.52%
0.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Verrica Pharmaceuticals stock?

Verrica Pharmaceuticals (VRCA) has a market cap of $296.08M as of April 24, 2024.

What is the P/E ratio for Verrica Pharmaceuticals stock?

The price to earnings (P/E) ratio for Verrica Pharmaceuticals (VRCA) stock is 0 as of April 24, 2024.

Does Verrica Pharmaceuticals stock pay dividends?

No, Verrica Pharmaceuticals (VRCA) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Verrica Pharmaceuticals dividend payment date?

Verrica Pharmaceuticals (VRCA) stock does not pay dividends to its shareholders.

What is the beta indicator for Verrica Pharmaceuticals?

Verrica Pharmaceuticals (VRCA) has a beta rating of 1.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Verrica Pharmaceuticals stock price target?

The target price for Verrica Pharmaceuticals (VRCA) stock is $13, which is 89.78% above the current price of $6.85. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Verrica Pharmaceuticals stock

Buy or sell Verrica Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing